The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.
 
Mehdi Brahmi
Honoraria - Amgen
Expert Testimony - Bayer
Travel, Accommodations, Expenses - mundipharma; PharmaMar
 
Julien Gautier
No Relationships to Disclose
 
Armelle Dufresne
No Relationships to Disclose
 
Perrine Marec-Berard
No Relationships to Disclose
 
Claire Cropet
No Relationships to Disclose
 
Séraphine Vizoso
No Relationships to Disclose
 
Laurie Bissuel
No Relationships to Disclose
 
Thibaud Valentin
No Relationships to Disclose
 
Natacha Entz-Werle
No Relationships to Disclose
 
Emmanuelle Bompas
No Relationships to Disclose
 
Maud Toulmonde
Speakers' Bureau - Blueprint Medicines
Travel, Accommodations, Expenses - PharmaMar
 
Elsa Kalbacher
Honoraria - AstraZeneca; LEO Pharma; Roche; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; Roche; Tesaro/GSK
Travel, Accommodations, Expenses - AstraZeneca; LEO Pharma; Roche; Tesaro/GSK
 
Florence Duffaud
Consulting or Advisory Role - Bayer Health; Bayer Health; BluPrint Oncology; GlaxoSmithKline
Travel, Accommodations, Expenses - Leo Pharma; PharmaMar
 
Nicolas Penel
Research Funding - Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Janssen-Cilag
Other Relationship - PharmaMar
 
Olivier Mir
Employment - Amgen
Stock and Other Ownership Interests - Amgen; Amplitude Surgical; Ipsen; Transgene
Honoraria - Roche
Consulting or Advisory Role - Janssen; Lilly; Lundbeck; Pfizer; Roche
Speakers' Bureau - Lilly; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Ipsen
Travel, Accommodations, Expenses - Pfizer; Roche
 
Justine Gantzer
No Relationships to Disclose
 
Pascaline Boudou-Rouquette
Honoraria - Ipsen
Consulting or Advisory Role - Takeda; Takeda
Travel, Accommodations, Expenses - PharmaMar; Takeda
 
Nelly Firmin
No Relationships to Disclose
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; DECIPHERA; Genmab; GlaxoSmithKline; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; BMS; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Macrogenics; Mersana; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Roche; Seagen; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche